Part 9/11:
Critics argue that such measures could lead to drug shortages and delays in clinical trials, hampering the development pipeline. A survey of pharma executives indicated that over 90% believe the Biosecure Act would slow their drug development processes. The pandemic underscored vulnerabilities in global supply chains—particularly reliance on Chinese manufacturing for essential goods like masks, medical equipment, and drugs—prompting US policymakers to seek greater self-sufficiency.